Physician Survey on SGLT2 Inhibitor Prescribing Barriers in Jordan

312 physicians, including 214 treating and 98 insurance physicians, participated in a 2026 mixed-methods study on barriers to prescribing SGLT2 inhibitors for heart failure in Jordan. The research, authored by Zekrayat J. H. Merdas and shared via figshare, integrated a cross-sectional survey with semi-structured interviews to analyze knowledge, attitudes, and systemic obstacles.

Use Cases

• Analyze the correlation between insurance physician misclassification of SGLT2 inhibitors as diabetes-only medications and approval rejection rates.
• Model predictors of insurance approval using survey-derived variables like prescriber specialty and guideline-aligned protocol availability.
• Compare knowledge and attitude scores between treating physicians and insurance physicians regarding SGLT2 inhibitor use in heart failure.

Strengths

• 312 physician survey responses provide a quantitative foundation.
• Integrated mixed-methods design combines survey statistics with qualitative thematic analysis.
• Specific findings quantify key barriers, such as 61.2% misclassification rate among insurance physicians.

Limitations

• 21.1 KB size indicates the dataset is a summary document, not raw survey data.
• Unknown row and column counts prevent direct computational analysis.
• Findings are specific to Jordan's healthcare context, limiting generalizability.

Provenance

Source

Zekrayat J. H. Merdas via figshare.

Collection Method

Explanatory sequential mixed-methods design using a cross-sectional survey and semi-structured interviews.

Time Range

Study conducted circa 2026.

Freshness

Last updated April 2026.

Geography

Jordan.